In this phase I study CG7870 was administered as a single intravenous infusion in a group-sequential dose escalation design (1 × 1010 to 6 × 1012 viral particles (vp)) to 23 patients with hormone-refractory metastatic prostate cancer.
This single-center, open-label, sequential dose-escalation study of lenvatinib was conducted at the National Cancer Center Hospital, Tokyo, Japan.
A Phase I, open-label, sequential-group dose escalation study was conducted to assess the tolerability, safety, and pharmacokinetics of micafungin in pediatric patients with neutropenia.
Forty-eight participants consented, enrolled, and received their assigned injection at study entry between the months of April and September 2005, in two sequential groups to permit dose escalation.
Vorinostat was administered 3 h before each radiotherapy treatment, with patients enrolled onto four sequential dose levels of vorinostat with dose escalation in increments of 100 mg (100 400 mg daily).
Dose escalation by a sequential boost regimen results in a longer treatment duration.
This was an open-label nonrandomised dose escalation study, conducted in sequential cohorts of patients from two institutions, Aberdeen Royal Infirmary, Aberdeen, and the Beatson Oncology Centre, Glasgow.
Dose escalation occurred via cohorts.
Thus, no further dose escalation was performed.
Design: Randomized, controlled, single-blind phase II dose escalation trial.
A 3 + 3 dose escalation design was employed.
